ATAI News and Press, ATAI Life Sciences N.V. From 04/17/23

The psychedelic renaissance is here, with numerous studies showing that psychedelics, including LSD, psilocybin, MDMA and ketamine. may be useful in the treatment of mental health conditions , such as addiction, depression, anxiety and psychological distress. Veteran religion journalist Don La...

2023-04-13 15:36:07 ET German biotech Atai Life Sciences ( NASDAQ: ATAI ) added 12% Thursday after announcing investigators have dosed the first participant in a Phase 1 study for PCN-101, a candidate targeted at treatment-resistant depression (TRD). Atai ( ATAI ) comp...

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience...

The first psychedelic facilitators at the Changa Institute passed their final exams . The 13 individuals will become the first physicians in the United States to be licensed to guide patients through psychedelic experiences outside of clinical trials. A recent surge in psychedelic research has r...

2023-03-31 14:49:06 ET Shares of Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company that is developing therapies from psychedelics to treat mental health conditions, saw its shares rise 12.41% by Friday afternoon. The stock had already been climbing a...

2023-03-31 09:53:39 ET Atai Life Sciences (NASDAQ: ATAI) , a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of trading this week. Specifically, the biotech's stock gained...

The past few years have seen the emergence of a relatively new and controversial mode of treatment in the psychiatric sector: psychedelic-assisted therapies . As more scientists across the country have turned their attention to psychedelics and its possible benefits, a growing body of research h...

2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...

2023-03-24 07:23:35 ET ATAI Life Sciences press release ( NASDAQ: ATAI ): Q4 GAAP EPS of -$0.28 misses by $0.05 . Revenue of $0.04M (-82.6% Y/Y) misses by $0.07M . Cash and cash equivalents and short-term investments were $273.1 million as of December 31, 2022,...

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditions Continued operational progress on robust clinical pipeline, with multiple phase 1 and phase 2 proof-of-...